Hartley, Jordan and Abken, Hinrich (2019) Chimeric antigen receptors designed to overcome transforming growth factor-beta-mediated repression in the adoptive T-cell therapy of solid tumors. CLINICAL & TRANSLATIONAL IMMUNOLOGY, 8 (6): e1064. ISSN 2050-0068
Full text not available from this repository. (Request a copy)Abstract
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells produced lasting remissions in the treatment of advanced, so far refractory B-cell malignancies; however, the elimination of solid tumors remains so far elusive. The low efficacy of CAR T cells is thought to be due to the immune-repressive milieu within the tumor lesion, predominantly mediated by transforming growth factor-beta (TGF-beta) that represses effector T-cell activities and drives differentiation towards regulatory T cells (Tregs). Seeking to boost antitumor immunity, TGF-beta is currently targeted by different means in pre-clinical studies. While a recent clinical trial showed the utility of shielding CAR T cells from TGF-beta repression, further strategies in counteracting TGF-beta in the adoptive cell therapy warrant exploration. We here discuss the most recent advances in the field and draw future developments to make CAR T-cell therapy more potent in the treatment of solid cancer.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TGF-BETA; SIGNALING PATHWAY; CD8(+); CD4(+); HOMEOSTASIS; EXPANSION; adoptive T-cell therapy; chimeric antigen receptor; immunosuppression; immunotherapy; TGF-beta |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Regensburger Centrum für Interventionelle Immunologie (RCI) |
| Depositing User: | Petra Gürster |
| Date Deposited: | 26 Mar 2020 09:35 |
| Last Modified: | 26 Mar 2020 09:35 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27797 |
Actions (login required)
 |
View Item |
